Catalyst Biosciences, Inc. (CBIO)
| Previous Close | 0.3800 |
| Open | 0.4199 |
| Bid | 0.3800 x 800 |
| Ask | 0.3999 x 900 |
| Day's Range | 0.3706 - 0.4199 |
| 52 Week Range | 0.3500 - 5.2000 |
| Volume | |
| Avg. Volume | 5,018,588 |
| Market Cap | 11.936M |
| Beta (5Y Monthly) | 1.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.0550 |
| Earnings Date | Mar 02, 2022 - Mar 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Aug 20, 2015 |
| 1y Target Est | 11.33 |
- GlobeNewswire
Catalyst Biosciences Sells Complement Portfolio for $60 Million
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) under which Vertex has acquired Catalyst’s portfolio of protease medicines that regulate complement, including CB 2782-PEG, for $60 million in cash. Management Comments“We have been exploring strategic alternatives to monetize our assets and maximize value f
- GlobeNewswire
Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results
SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2022. “In the first quarter, we regained the rights to CB 2782-PEG, a C3 degrader protease, for the potential treatment of dry age-related macular degeneration (“AMD”) and now have full rights to two wholly-owned, potential best-in-class complement candidates that may provide compelling opportunities in o
- Simply Wall St.
Here's Why Catalyst Biosciences (NASDAQ:CBIO) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
